



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: IZUMOTO=1

In re Application of: ) Conf. No.: Not Yet Known  
Yoshitaka IZUMOTO et al ) Art Unit: Not Yet Known  
U.S. Appln. No.: 10/553,694 ) Examiner: Not Yet Known  
Filed: October 18, 2005 )  
I.A. No.: PCT/JP2004/005501 )  
I.A. Filed: April 16, 2004 ) Washington, D.C.  
For: IMMUNOGEN, COMPOSITION FOR ) September 12, 2006  
IMMUNOLOGICAL USE AND )  
METHOD FOR PRODUCING ANTI-)   
BODY USING THE SAME )

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop Amendment  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s),

which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

3. Document AY is not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states an English translation of document AY (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:

Supplementary European Search Report mailed June 30, 2006

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By: 

Anne M. Kornbau  
Registration No. 25,884

AMK:ma  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

G:\BN\F\FUJI\Izumoto\1\PTO\2006-09-11 IDS-Form Re-submitted.doc



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 1

## Complete if Known

U.S. Application Number	10/553,694
I.A. Filing Date	April 16, 2004
First Named Inventor	Yoshitaka IZUMOTO et al
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	IZUMOTO=1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AY	WO 02/052029 A1	07-04-2002	SEKISUI CHEMICAL CO. LTD.		Abs
	AZ	WO 03/000878 A2	01-03-2003	Christian SCHOLZ et al.		
	BA	WO 00/75346 A1	12-14-2000	Alan FERSHT		

## NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BB	J. WINTER et al., "Increased production of human proinsulin in the periplasmic space of <i>Escherichia coli</i> by fusion to DsbA", <i>Journal of Biotechnology</i> , Vol. 84, pp. 175-185, 2000.	

Examiner  
Signature

/Patricia Duffy/

Date  
Considered

04/13/2008

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is provided.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./